Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-25T07:16:25.493Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction

Published online by Cambridge University Press:  06 August 2018

Jeffrey A. Lieberman  and
W. Wolfgang Fleischhacker
Jeffrey A. Lieberman
Affiliation:
Department of Psychiatry and Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA
W. Wolfgang Fleischhacker
Affiliation:
Department of Biological Psychiatry, Innsbruck University Hospital, Innsbruck, Austria
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
The British Journal of Psychiatry , Volume 168 , Issue S29: Current Issues in the Development of Atypical Antipsychotic Drugs , May 1996 , pp. 7 - 8
Copyright
Copyright © 1996 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldessarini, R. J. & Frankenburg, F. R. (1991) Clozapine. A novel antipsychotic agent. New England Journal of Medicine, 14, 746–754.Google Scholar
Carpenter, W. T. & Buchanan, R. W. (1989) Domains of psychopathology relevant to the study of etiology and treatment of schizophrenia. In Schizophrenia: A Scientific Focus (eds Schultz, S. C. & Tamminga, C. T.). New York: Oxford University Press.Google Scholar
Creese, I., Burt, D. R. & Snyder, S. H. (1975) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481–483.Google Scholar
Delay, J., Deniker, P. & Hart, J. (1952) Traitment des états d'excitation et d'agitation par une méthode médicamenteus dérivée del'hibernothérapie. Annates Medico-Psychologiques, 1110, 267–273.Google Scholar
Gardos, G. & Cole, J. (1976) Maintenance antipsychotic therapy: is the cure worse than the disease? American Journal of Psychiatry, 133, 32–36.Google Scholar
Kane, J. M. & Lieberman, J. A. (1992) Adverse Effects of Psychotropic Drugs. New York: Guilford Press.Google Scholar
Kane, J. M. & Marder, S. R. (1993) Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19, 287–302.CrossRefGoogle ScholarPubMed
Lieberman, J. A. (1993) Understanding the mechanisms of atypical antipsychotic drugs: review of compounds in use and development. British Journal of Psychiatry, 163 (suppl. 22), 7–18.Google Scholar
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 184, 825–835.Google Scholar
Meltzer, H. Y., Matsubara, S. & Lee, J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 238–246.Google Scholar
Snyder, S. H., Banarjee, S. P. & Yamamura, H. T. (1974) Drugs, neurotransmitters and schizophrenia. Science, 184, 1243–1253.Google Scholar
Strauss, J. & Carpenter, W. T. Jr (1977) Prediction of outcome in schizophrenia III. Five-year outcome and its prediction. Archives of General Psychiatry, 34, 159–163.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.